Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zecdarasib + navlimetostat
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
zecdarasib + navlimetostat (INCB161734 + BMS-986504) is an investigational combination therapy being developed for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The combination consists of zecdarasib, an oral, selective, non-covalent small-molecule KRAS G12D inhibitor developed by Incyte, and navlimetostat, an oral, MTA-cooperative PRMT5 inhibitor developed by Bristol Myers Squibb (originally Mirati Therapeutics). Zecdarasib targets both the active (ON) and inactive (OFF) states of mutant KRAS G12D, which is a major oncogenic driver in pancreatic and colorectal cancers. Navlimetostat selectively targets the PRMT5-MTA complex, exploiting synthetic lethality in MTAP-deleted tumor cells. The combination leverages the synergistic potential of co-targeting the KRAS pathway and PRMT5/MTA axis in MTAP-deleted, KRAS-mutant pancreatic cancers. In late 2026, Incyte announced a clinical trial collaboration with Bristol Myers Squibb to evaluate this combination in a Phase 1b trial for patients with advanced or metastatic PDAC.
- Other names
- INCB161734 + BMS-986504INCB161734 + MRTX1719INCB161734 + navlimetostatnavlimetostatzecdarasibzecdarasib + BMS-986504zecdarasib + MRTX1719zecdarasib + navlimetostat
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)PRMT5 (Protein arginine N-methyltransferase 5)
Beyond the preview
Go deeper on zecdarasib + navlimetostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zecdarasib + navlimetostat.